— Physician executive with experience in multiple sectors of healthcare, including care delivery, health insurance, government, and industry will guide ICER in its mission to achieve a health system in which all patients benefit from fair pricing, fair access, and future innovation —
September 7, 2023 – The Institute for Clinical and Economic Review (ICER) today announced the election of a new member to the ICER Governance Board: Roberta Herman, MD, CEO and President of Joslin Diabetes Center. ICER’s Governance Board provides strategic counsel to ICER’s leadership team while maintaining fiduciary responsibility for the organization’s overall operations.
“Dr. Herman has had a remarkable career of leadership across many sectors in the US health care system,” said Sarah Emond, MPP, President-Elect of ICER. “She cares deeply about the use of evidence to improve outcomes for patients, and her expertise from the provider, purchaser, and industry perspectives will strengthen ICER’s ability to help the US health system provide better access to high-value care that all Americans can afford.”
Dr. Herman stated, “I’m looking forward to supporting ICER’s goal of using the best scientific methods available to ground a more transparent process through which patients can be guaranteed fair prices, fair access, and a health care system primed for future innovation. ICER’s conclusions are objective, credible, and crucial for public policy discussions.”
Dr. Herman is the CEO and President of the Joslin Diabetes Center; previously she also served on their Board of Trustees. Dr. Herman has significant experience in health policy and payer sectors as well. For four years, she was the Executive Director of the Group Insurance Commission (GIC) under the Baker Administration; a quasi-independent $2B+ agency that procures and administers health insurance and other benefits for more than 450,000 employees and retirees for Commonwealth of Massachusetts and their dependents. Dr. Herman also co-led the Healthcare Value Transformation Practice at Navigant (now Guidewell). Finally, she was the Chief Medical Officer and subsequently Chief Operating Officer for Harvard Pilgrim Health Care (now Point32Health), one of New England’s largest non-profit managed health care organizations, providing care and coverage to more than one million members throughout Massachusetts, Maine and New Hampshire. During her tenure, HPHC became the #1 Health Plan in the US according to NCQA, a position it maintained for more than a decade.
Dr. Herman is originally from Montreal, Canada, where she trained as an Internist and Epidemiologist at McGill University and the Royal Victoria Hospital. She has been a Clinical Instructor at Harvard Medical School and has held hospital appointments at Mount Auburn Hospital, Beth Israel Deaconess Medical Center, and Brigham and Women’s Hospital. She has also served as a guest lecturer at the Harvard School of Public Health.
For more information on ICER’s Governance Board, click here.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.